Highlights for MRD assessment in AML

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE, about the highlights for measurable residual disease (MRD) assessment in AML from ASH 2020.

Bullinger mentions three studies presented at ASH 2020: the first one investigating the effectiveness of MRD eradication with chemotherapy prior to allogeneic stem cell transplantation in AML; the second study evaluating NPM1 as a molecular marker for MRD; and the last one focusing on new technologies for MRD assessment.

Bullinger kindly gave his interview in German, with the title 'ASH 2020: Highlights zum MRD Monitoring bei der AML'.